• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
European Injectable Drug Delivery - Market Forecasts to 2017 - Product Image Special Offer Sale Banner

European Injectable Drug Delivery - Market Forecasts to 2017

  • ID: 2586891
  • July 2013
  • Region: Europe
  • 333 Pages
  • Markets and Markets
Special Offer Banner
10%
OFF
Offer ends 31st Dec 2014

FEATURED COMPANIES

  • Alkermes, Inc
  • Crossject
  • Gerresheimer AG
  • Haselmeier Gmbh
  • Novo Nordisk A/S
  • Owen Mumford, Ltd
  • MORE

European Injectable Drug Delivery Market By Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] - Forecasts to 2017

This research report categorizes the European injectable drug delivery technologies market into two segments, namely, Europe injectable drug delivery devices technologies and European injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (Germany, France, U.K., Spain, Italy, Russia and Rest of Europe (RoE)) to provide in-depth information on the European scenario.

The European injectable drug delivery technologies market was valued at $6.8 billion in 2012, and is expected to reach $12.4 billion by 2017 at a CAGR of 12.7% from 2012 to 2017. Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkermes, Inc
  • Crossject
  • Gerresheimer AG
  • Haselmeier Gmbh
  • Novo Nordisk A/S
  • Owen Mumford, Ltd
  • MORE

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions

2 Executive Summary

3 Market Overview
3.1 Introduction
3.2 Market Segmentation
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Technological Advancements
3.3.1.2 Favorable Reimbursement Environment To Bolster The Demand Of Self Injection Devices
3.3.1.3 Surge Of Biologics In European Pharmaceutical Market
3.3.1.4 Rising Incidences Of Cancer And Diabetes
3.3.1.5 Improving Patient Compliance
3.3.2 Restraints
3.3.2.1 Needle-Stick Injuries And Infections
3.3.2.2 Threat From Alternate Drug Delivery Methods
3.3.2.3 Slow Approval Process Of Drugs And Medical Devices In Europe
3.3.3 Opportunities
3.3.3.1 Development Of Biosimilars In The European Pharmaceutical Market
3.3.3.2 Need For Better Healthcare For The Increasing Geriatric Population Of Europe
3.3.4 Challenges
3.3.4.1 Sustainability Of Players In Highly Competitive Market
3.4 Market Share Analysis, By Major Players
3.4.1 Conventional Injectable Drug Delivery Devices
3.4.2 Self-Injection Devices-Pen Injectors

4 European Injectable Drug Delivery Devices Technologies Market
4.1 Introduction
4.2 Market Segmentation
4.3 Manufacturers Criteria For Selection Of An Injectable Device
4.4 Conventional Injectable Drug Delvery Devices
4.4.1 By Usability
4.4.1.1 Disposable
4.4.1.2 Reusable
4.4.2 By Material
4.4.2.1 Glass
4.4.2.2 Plastic
4.4.3 By Product
4.4.3.1 Fillable
4.4.3.2 Prefilled
4.5 Self-Injection Devices
4.5.1 Market Segmentation
4.5.2 Selection Criteria For Self-Injection Device
4.5.3 Pen Injectors
4.5.3.1 By Product
4.5.3.1.1 Single Chamber Pen Injectors
4.5.3.1.2 Dual Chamber Pen Injectors
4.5.3.2 By Usability
4.5.3.2.1 Disposable Pen Injectors
4.5.3.2.2 Reusable Pen Injectors
4.5.3.3 By Design
4.5.3.3.1 Standard Pen Injectors
4.5.3.3.2 Customized Pen Injectors
4.5.4 Needle-Free Injectors
4.5.4.1 By Product
4.5.4.1.1 Prefilled Needle Free Injectors
4.5.4.1.2 Fillable Needle Free Injectors
4.5.4.2 By Technology
4.5.4.2.1 Jet-Based Needle-Free Injectors
4.5.4.2.2 Spring-Based Needle-Free Injectors
4.5.4.2.3 Laser-Based Needle Free Injectors
4.5.4.2.4 Vibration-Based Needle Free Injectors
4.5.4.3 By Usability
4.5.4.3.1 Disposable
4.5.4.3.2 Reusable
4.5.5 Auto Injectors
4.5.5.1 By Product
4.5.5.1.1 Prefilled Auto Injectors
4.5.5.1.2 Fillable Auto Injectors
4.5.5.2 By Technology
4.5.5.2.1 Automated Auto Injectors
4.5.5.2.2 Manual Auto Injectors
4.5.5.3 By Design
4.5.5.3.1 Standardized Auto Injectors
4.5.5.3.2 Customized Auto Injectors
4.5.5.4 By Usability
4.5.5.4.1 Disposable Auto Injectors
4.5.5.4.2 Reusable Auto Injectors
4.6 Others

5 European Injectable Drug Delivery Formulation Technologies Market
5.1 Introduction
5.2 Conventional Drug Delivery
5.2.1 Injectable Solutions
5.2.2 Reconstituted/Lyophilized Formulations
5.3 Novel Drug Delivery Formulation Technologies
5.3.1 Market Segmentation
5.3.2 Liposomal Systems
5.3.3 Microspheres
5.3.4 Nanoparticles
5.3.5 Polymeric Micelles
5.3.6 Others

6 European Injectable Drug Delivery Technologies Market, By Therapeutic Applications
6.1 Introduction
6.2 Auto-Immune Diseases
6.2.1 Multiple Sclerosis
6.2.2 Rheumatoid Arthritis
6.2.3 Crohn's Diseases
6.2.4 Psoriasis
6.2.5 Others
6.3 Hormonal Disorders
6.3.1 Diabetes
6.3.2 Anemia
6.3.3 Reproductive Health Diseases
6.3.4 Antithrombotic/Thrombolytic Therapy
6.3.5 Osteoporosis
6.3.6 Growth Hormone Deficiency
6.4 Orphan/Rare Diseases
6.5 Oncology
6.6 Others
6.6.1 Pain Management
6.6.2 Hepatitis C
6.6.3 Allergies
6.6.4 Aesthetic Treatment

7 Geographic Analysis
7.1 Introduction
7.2 Germany
7.2.1 More Than 25 New Medicines Are Due For Marketing License In Germany For The Year 2013
7.3 France
7.3.1 Higher Insurance Coverage, Increase In Aging Population And Affordability Drives The Market In France
7.4 U.K.
7.4.1 Highest Turnover Of Antibiotics And Small Molecules Due To Oncology And Infections
7.4.2 Bioscience & Health Technology Database Provide Better Industry Data On Injectable Technologies
7.5 Spain
7.5.1 Spain Is Amongst The Top 10 Countries With Highest Expenditure On Diabetes
7.6 Italy
7.6.1 Removal Of Linkages Between Patent And Generic Medicines Causes Rapid Access To Generics In Italy
7.7 Russia
7.7.1 Russian Government Aimed To Foster The Development Of Healthcare System
7.8 Rest Of Europe
7.8.1 Switzerland Has The Most Competitive Economy And Has Leading Position In Global Pharmaceuticals And Biotech Industries
7.8.2 Denmark Provides For Concentrated Patient Pool Especially For Diabetes Due To Centralization Of Healthcare System
7.8.3 High Acceptability For New Technologies And Lowest Corporate Tax Rate Drives The Ireland Market
7.8.4 Favorable Growth In Regions Of Portugal, Poland, And Romania Due To Increasing Diabetes Incidence And Related Reimbursement Policies

8 Competitive Landscape
8.1 Introduction
8.2 Expansion
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 New Product Launch
8.5 Mergers & Acquisitions
8.6 Other Developments

9 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Alkermes, Inc.
9.2 Bespak Europe, Ltd. (Subsidiary Of Consort Medical, Plc)
9.3 Crossject
9.4 Gerresheimer AG
9.5 Haselmeier Gmbh
9.6 Injex Pharma Gmbh (Subsidiary Of Hns International, Inc.)
9.7 Novo Nordisk A/S
9.8 Owen Mumford, Ltd.
9.9 Sanofi
9.10 Schott AG
9.11 Vetter Pharma-Fertigung Gmbh & Co. KG
9.12 Ypsomed Holding AG
*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

List Of Tables

Table 1 Europe Injectable Drug Delivery Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 2 Europe Injectable Drug Delivery Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 3 Injection Drug Delivery Technologies Market, By Geography, 2010 – 2017 ($Million)
Table 4 Europe Injectable Drug Delivery Devices Technologies Market, By Product, 2010 – 2017 ($Million)
Table 5 Injection Drug Delivery Devices Technologies Market, By Geography, 2010 – 2017 ($Million)
Table 6 Conventional Injection Devices Market, By Geography, 2010 – 2017 ($Million)
Table 7 European Conventional Injection Devices Market, By Usability, 2010 – 2017 ($Million)
Table 8 Disposable Conventional Devices Market, By Geography, 2010 – 2017 ($Million)
Table 9 Reusable Conventional Devices Market, By Geography, 2010 – 2017 ($Million)
Table 10 European Conventional Injection Devices Market, By Material, 2010 – 2017 ($Million)
Table 11 Conventional Injection Devices (Glass) Market, By Geography, 2010 – 2017 ($Million)
Table 12 Conventional Injection Devices (Plastic) Market, By Geography, 2010 – 2017 ($Million)
Table 13 European Conventional Injection Devices Market, By Product, 2010 – 2017 ($Million)
Table 14 Fillable Conventional Injection Devices Market, By Geography, 2010 – 2017 ($Million)
Table 15 Prefilled Conventional Injection Devices Market, By Geography, 2010 – 2017 ($Million)
Table 16 Major Therapeutic Areas For Self-Injection Devices
Table 17 Europe Self-Injection Devices Market, By Product, 2010 – 2017 ($Million)
Table 18 Self-Injection Devices Market, By Geography, 2010 – 2017 ($Million)
Table 19 Pen Injector Market, By Geography, 2010 – 2017 ($Million)
Table 20 European Pen Injectors Market, By Product, 2010 – 2017 ($Million)
Table 21 Single Chamber Pen Injector Market, By Geography, 2010 – 2017 ($Million)
Table 22 Dual Chamber Pen Injector Market, By Geography, 2010 – 2017 ($Million)
Table 23 European Pen Injectors Market, By Usability, 2010 – 2017 ($Million)
Table 24 Disposable Pen Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 25 Reusable Pen Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 26 European Pen Injectors Market, By Design, 2010 – 2017 ($Million)
Table 27 Standard Pen Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 28 Customized Pen Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 29 Needle Free Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 30 European Needle Free Injectors Market, By Product, 2010 – 2017 ($Million)
Table 31 Prefilled Needle Free Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 32 Fillable Needle Free Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 33 European Needle Free Injectors Market, By Technology, 2010 – 2017 ($Million)
Table 34 Jet-Based Needle Free Injector Market, By Geography, 2010 – 2017 ($Million)
Table 35 Spring-Based Needle Free Injector Market, By Geography, 2010 – 2017 ($Million)
Table 36 Laser-Powered Needle Free Injector Market, By Geography, 2010 – 2017 ($Million)
Table 37 Vibration-Based Needle Free Injector Market, By Geography, 2010 – 2017 ($Million)
Table 38 Europe Needle Free Injectors Market, By Usability, 2010 – 2017 ($Million)
Table 39 Disposable Needle Free Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 40 Reusable Needle Free Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 41 Auto Injectors Products Market, By Geography, 2010 – 2017 ($Million)
Table 42 Europe Auto Injectors Market, By Product, 2010 – 2017 ($Million)
Table 43 Prefilled Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 44 Fillable Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 45 Europe Auto Injectors Market, By Technology, 2010 – 2017 ($Million)
Table 46 Automated Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 47 Manual Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 48 Europe Auto Injectors Market, By Design, 2010 – 2017 ($Million)
Table 49 Standardized Auto Injectors Market, By Geography,2010 – 2017 ($Million)
Table 50 Customized Auto Injectors Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 51 Europe Auto Injectors Market, By Usability, 2010 – 2017 ($Million)
Table 52 Disposable Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 53 Reusable Auto Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 54 Others Injectors Market, By Geography, 2010 – 2017 ($Million)
Table 55 Europe Injectable Drug Delivery Formulation Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 56 Injectable Drug Delivery Formulation Technologies Market, By Geography, 2010 – 2017 ($Million)
Table 57 Europe Conventional Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 58 Conventional Drug Delivery Formulation Technologies Market, By Geography, 2010 – 2017 ($Million)
Table 59 Injectable Solutions Conventional Drug Delivery Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 60 Reconstituted/Lyophilized Conventional Drug Delivery Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 61 Novel Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 62 Novel Drug Delivery Formulation Technologies Market, By Geography, 2010 – 2017 ($Million)
Table 63 Liposome Drug Delivery Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 64 Microspheres Drug Delivey Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 65 Nanoparticles Drug Delivey Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 66 Polymeric Micelles Drug Delivey Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 67 Other Novel Drug Delivey Formulation Market, By Geography, 2010 – 2017 ($Million)
Table 68 Europe Injectable Drug Delivery Technologies Market, By Therapeutic Application, 2010 – 2017 ($Million)
Table 69 Europeauto-Immune Therapeutic Market, By Indication, 2010 – 2017 ($Million)
Table 70 Auto-Immune Therapeutic Market,By Geography, 2010 – 2017 ($Million)
Table 71 Multiple Sclerosis Market, By Geography, 2010 – 2017 ($Million)
Table 72 Rheumatoid Arthritis Market, By Geography, 2010 – 2017 ($Million)
Table 73 Crohn's Diseases Market, By Geography, 2010 – 2017 ($Million)
Table 74 Psoriasis Market, By Geography, 2010 – 2017 ($Million)
Table 75 Other Auto-Immune Diseases Market, By Geography, 2010 – 2017 ($Million)
Table 76 Europe Hormonal Disorders, By Indication, 2010 – 2017 ($Million)
Table 77 Hormonal Disorders Market, By Geography, 2010 – 2017($Million)
Table 78 Diabetes Market, By Geography, 2010 – 2017 ($Million)
Table 79 Anemia Market, By Geography, 2010 – 2017 ($Million)
Table 80 Reproductive Health Diseases Market, By Geography,2010 – 2017($Million)
Table 81 Antithrombotic Therapy Market, By Geography, 2010 – 2017 ($Million)
Table 82 Osteoporosis Market, By Geography, 2010 – 2017 ($Million)
Table 83 Growth Hormone Deficiency Market, By Geography, 2010 – 2017 ($Million)
Table 84 Orphan/Rare Diseases Therapeutic Market, By Geography, 2010 – 2017 ($Million)
Table 85 Oncology Therapeutic Market, By Geography, 2010 – 2017 ($Million)
Table 86 European Other Therapeutic Market, 2010 – 2017 ($Million)
Table 87 Other Therapeutic Market, By Geography, 2010 – 2017 ($Million)
Table 88 Pain Management Market, By Geography, 2010 – 2017 ($Million)
Table 89 Hepatitis C Market, By Geography, 2010 – 2017 ($Million)
Table 90 Allergies/Anaphylytic Shock Market, By Geography, 2010 – 2017 ($Million)
Table 91 Aesthetic Treatment Market, By Geography, 2010 – 2017 ($Million)
Table 92 Germany: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 93 Germany: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 94 Germany: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 95 Germany: Injectable Drug Delivery Technologies Market, By Therapeutic Application, 2010 – 2017 ($Million)
Table 96 France: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 97 France: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 98 France: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 99 France: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 100 U.K.: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 101 U.K.: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 102 U.K.: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 103 U.K.: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 104 Spain: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 105 Spain: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 106 Spain: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 107 Spain: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 108 Italy: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 109 Italy: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 110 Italy: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 111 Italy: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 112 Russia: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 113 Russia: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 114 Russia: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 115 Russia: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 116 ROE: Injectable Drug Delivery Technologies Market, 2010 – 2017 ($Million)
Table 117 ROE: Injectable Drug Delivery Devices Technologies Market, By Segment, 2010 – 2017 ($Million)
Table 118 ROE: Injectable Drug Delivery Formulation Technologies Market, 2010 – 2017 ($Million)
Table 119 ROE: Injectable Drug Delivery Technologies Market, By Therapeutic Application 2010 – 2017 ($Million)
Table 120 Expansion, 2010 – 2013
Table 121 Agreements, Partnerships, Collaborations & Joint Ventures, 2010 – 2013
Table 122 New Product Launch, 2010 – 2013
Table 123 Mergers & Acquisitions, 2010 – 2013
Table 124 Other Developments, 2010 – 2013
Table 125 Alkermes: Total Revenue And R&D Expenses, 2009 – 2011 ($Million)
Table 126 Alkermes: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 127 Consort Medical: Total Revenue And R&D Expense, 2009 – 2011 ($Million)
Table 128 Consort Medical: Total Revenue, By Geography, 2009 – 2011 ($Million)
Table 129 Gerresheimer Ag: Total Revenue And R&D Expenses, 2010 – 2012 ($Million)
Table 130 Gerresheimer Ag: Total Revenue, By Segment, 2010 – 2012 ($Million)
Table 131 Gerresheimer Ag: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 132 Novo Nordisk: Total Revenue And R&D Expenses, 2010 – 2012 ($Billion)
Table 133 Novo Nordisk: Total Revenue, By Segment, 2010 – 2012 ($Billion)
Table 134 Novo Nordisk: Total Revenue, By Geography, 2010 – 2012 ($Billion)
Table 135 Sanofi: Total Revenue & R&D Expenditure, 2010 – 2012 ($Billion)
Table 136 Sanofi: Total Revenue, By Segment, 2010 - 2012 ($Billion)
Table 137 Sanofi: Total Revenue, By Geography, 2010 - 2012 ($Billion)
Table 138 Schott Ag: Total Revenue And R&D Expenditures, 2010 – 2012 ($Million)
Table 139 Schott Ag: Total Revenue, By Geography, 2010 – 2012 ($Million)
Table 140 Ypsomed: Total Revenue And R&D Expenses, 2009 - 2011 ($Million)
Table 141 Ypsomed: Total Revenue, By Segment, 2009 - 2011 ($Million)
Table 142 Ypsomed: Total Revenue, By Geography, 2009 ($Million)
Table 143 Ypsomed: Total Revenue, By Geography, 2010 - 2011 ($Million)

List Of Figures (26 Figures)

Figure 1 Europe Injectable Drug Delivery Technologies Market, By Segment, 2012 & 2017
Figure 2 Injectable Drug Delivery Technologies Market, By Geography, 2012
Figure 3 Injectable Drug Delivery Technologies Market Segmentation
Figure 4 Injectable Drug Delivery Technologies Market Segmentation
Figure 5 Market Segmentation Of Injectable Drug Delivery Technologies, By Therapeutic Application
Figure 6 Injectable Drug Delivery Technologies Market Dynamics
Figure 7 Europeconventional Injection Devices Market, By Key Players, 2012 ($Million)
Figure 8 European Pen Injectors Market, By Key Players, 2012 ($Million)
Figure 9 Injectable Drug Delivery Devices Technologies Market Segmentation
Figure 10 Factors Affecting Selection Of An Injectable Device
Figure 11 European Self-Injection Devices Market, By Product, 2010 – 2017 ($Million)
Figure 12 Self-Injection Devices Market Segmentation
Figure 13 Factors Affecting Selection Of Self-Injection Device
Figure 14 Conventional Drug Delivery Formulation Technologies Market Segmentation
Figure 15 Europe Novel Drug Delivey Formulation Market, 2012 & 2017 ($Million)
Figure 16 Novel Drug Delivery Formulation Technologies Segmentation
Figure 17 Europe Injectable Drug Delivery Technologies Market, By Therapeutic Application, 2010 – 2017 ($Million)
Figure 18 Injectable Drug Delivery Technologies Market Segmentation, By Therapeutic Applications
Figure 19 Auto-Immune Therapeutic Market Segmentation
Figure 20 Hormonal Disorders Market Segmentation
Figure 21 Key Growth Strategies, 2010 – 2013
Figure 22 Key Growth Strategies, By Companies, 2010 – 2013
Figure 23 Geographical Expansions, By Company, 2010 – 2013
Figure 24 Agreements, Partnerships, Collaborations & Joint Ventures, By Company, 2010 – 2013
Figure 25 New Product Launch, By Company, 2010 – 2013
Figure 26 Mergers & Acquisitions, By Company, 2010 – 2013

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkermes, Inc
  • Crossject
  • Gerresheimer AG
  • Haselmeier Gmbh
  • Novo Nordisk A/S
  • Owen Mumford, Ltd
  • MORE

Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and development of nanotechnologies. Based on product type, the injectable drug delivery devices technologies market is further categorized as conventional injection devices, self-injection devices, and others (microneedles, nanoneedles and blunt needle injections), while the injectable drug delivery formulation technologies market is categorized as conventional drug delivery formulations and novel drug delivery formulations. The conventional injection devices segment accounted for the largest share of the European injectable drug delivery technologies market in 2012.

The market is also segmented on the basis of its therapeutic applications as auto immune diseases, hormonal imbalances, oncology, orphan/rare diseases (Hemophilia, Ribose-5-phosphate isomerase deficiency (RPI deficiency), Cystic Fibrosis, and Wilsons disease) and others (pain management, allergies, hepatitis C, and aesthetic treatment). Hormonal disorders commanded the largest share of the European injectable drug delivery technologies market in 2012.

The European injectable drug delivery technologies market has witnessed challenging and dynamic market conditions (due to technological advancements and surge of biologics and biosimilars in pharmaceutical market) over the last five years. Newer products with better safety and efficacy contribute to the widespread adoption of injectable drug delivery technologiesby physicians and patients. However, factors such as needle-stick injuries and infections and development of alternate delivery methods (oral, nasal and topical) for injectable drugs are restraining the growth of the market.

The key players in this market are Becton Dickinson & Co. (U.S.), Baxter International, Inc. (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Eli Lily & Co. (U.S.), Gerresheimer AG (Germany), Sanofi (France), West Pharmaceutical Services, Inc. (U.S.), Haselmeier GmbH (Germany), and Owen Mumford, Ltd. (U.K.).

Note: Product cover images may vary from those shown

- Alkermes, Inc
- Bespak Europe, Ltd (Subsidiary Of Consort Medical, Plc)
- Crossject
- Gerresheimer AG
- Haselmeier Gmbh
- Injex Pharma Gmbh (Subsidiary Of Hns International, Inc)
- Novo Nordisk A/S
- Owen Mumford, Ltd
- Sanofi
- Schott AG
- Vetter Pharma-Fertigung Gmbh & Co KG
- Ypsomed Holding AG

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos